Biotech company cuts validation time by 40% with Res_Q

A growing biotech company developing cancer and infectious disease treatments faced fragmented validation processes across multiple sites, requiring manual file exchanges and outdated workflows that created validation debt. The organization implemented Sware's Res_Q, a SaaS platform providing workflow automation, centralized documentation management, and unified validation control. The implementation achieved a "30-40% reduction in total validation time," improved audit-readiness and compliance visibility, and freed IT and Quality staff for higher-value work. The company is now collaborating with Sware to integrate custom bioinformatic data into Res_Q workflows.

Sware is a GxP validation platform whose entire commercial focus is life sciences — used specifically to validate AI/ML systems' explainable, traceable decisions for regulatory scrutiny.

This sits in the Scale & Govern stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to monitor, govern and keep validating an AI system once it is already live in production.